Advert - Novartis – Case AUTH/3400/10/20

Promotion of Inclisiran on a third party website

For promoting inclisiran (Leqvio) prior to the grant of the marketing authorisation, Novartis was ruled in breach of the following clauses of the Code:

Clause 2 - Bringing discredit upon, and reducing confidence in, the pharmaceutical
Clause 3.1 - Promoting an unlicensed medicine
Clause 9.1 - Failing to maintain high standards
Clause 9.10 - Failing to be sufficiently clear as to the company’s role and involvement
Clause 12.1 - Disguising promotional material
Clause 14.1 - Failing to certify promotional material
Clause 28.1 - Failing to comply with all relevant requirements of the Code